Medicus Pharma Ltd. Advances Non-Invasive Treatment for Basal Cell Carcinoma
TL;DR
Medicus Pharma Ltd.'s innovative SkinJect microneedle patch offers a competitive edge in the $15 billion BCC treatment market with its non-invasive, cost-effective solution.
SkinJect utilizes a patented dissolvable microneedle patch to deliver doxorubicin directly to tumor cells, demonstrating safety and efficacy in Phase I trials with Phase II underway.
Medicus Pharma's SkinJect patch represents a significant advancement in skin cancer treatment, offering a less painful, non-surgical option that could improve millions of lives globally.
Discover how Medicus Pharma's thumb-sized microneedle patch is revolutionizing skin cancer treatment, with promising Phase I results and a potential market impact of over $15 billion.
Found this article helpful?
Share it with your network and spread the knowledge!
Skin cancer, particularly basal cell carcinoma (BCC), represents a significant health challenge in the United States, with over 5 million cases diagnosed annually. Medicus Pharma Ltd. (NASDAQ:MDCX) is at the forefront of addressing this issue through its subsidiary SkinJect Inc., which is developing a thumb-sized, dissolvable microneedle patch for the non-invasive treatment of BCC. This innovative approach delivers doxorubicin directly to tumor cells, aiming to kill them and induce an immune response to prevent recurrence.
The company has made notable progress, with Phase I studies confirming the safety and tolerability of the treatment. A Phase 2 study is currently underway, with interim results showing over 60% complete clinical clearance in participants. The study's expansion to include more patients and additional sites in the U.S. and Europe, along with approval to commence trials in the UAE, underscores the treatment's potential global impact.
Beyond human applications, Medicus is exploring the use of its technology in veterinary medicine, specifically for treating squamous cell carcinoma in horses, a market with significant untapped potential. The company's strategic moves, including a planned acquisition of Antev Ltd. and a recent $7 million public offering, highlight its commitment to expanding its portfolio and advancing its clinical programs.
The potential market for SkinJect is vast, with BCC procedures expected to grow to 6 million by 2030, representing a $15 billion annual market. The treatment's advantages over traditional surgery, including lower cost, reduced pain, and quicker administration, position Medicus to capture a significant share of this market. With ongoing clinical trials and regulatory submissions, Medicus Pharma Ltd. is paving the way for a revolutionary approach to skin cancer treatment.
Curated from News Direct
